Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-12-04

Clinical Trial Update: Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria [Phase 4]

View source ↗

Summary

Phase 4 trial investigating the effect of omalizumab (Xolair) on basophils in patients with chronic idiopathic urticaria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Omalizumab (Omalizumab)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Chronic Urticaria | Phase 4 | Status: COMPLETED | Results posted: 2020-12-04